| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Active Not Recruiting | Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy NCT04692103 | University of Washington | Phase 2 |
| Recruiting | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764 | Mayo Clinic | Phase 1 |
| Completed | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Canc NCT03199885 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative M NCT03633331 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HE NCT03377101 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Br NCT03477396 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treatin NCT03101748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast C NCT03012230 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positi NCT03281902 | Mayo Clinic | — |
| Recruiting | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk NCT03418961 | SWOG Cancer Research Network | Phase 3 |
| Completed | Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer NCT03535701 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast NCT03106415 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Br NCT02971761 | City of Hope Medical Center | Phase 2 |
| Completed | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer NCT02673398 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Met NCT02778685 | City of Hope Medical Center | Phase 2 |
| Completed | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or B NCT02595905 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Co NCT02713269 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery NCT02658812 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrin NCT02398773 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies NCT02706392 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer NCT02474173 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estro NCT02311933 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 | M.D. Anderson Cancer Center | Phase 1 |
| Suspended | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage III NCT02037529 | Academic and Community Cancer Research United | Phase 3 |
| Terminated | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiv NCT01957514 | University of Washington | — |
| Completed | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Pa NCT01622868 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01624441 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer NCT01463072 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relaps NCT01434303 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer NCT01349959 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT01351909 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal NCT01344031 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive NCT01327781 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01251874 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Canc NCT02149173 | University of Washington | N/A |
| Completed | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer NCT01145430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Rec NCT01142401 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer NCT00699491 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or NCT00785291 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breas NCT00601900 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated NCT00684983 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cance NCT00390455 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT00376688 | National Cancer Institute (NCI) | Phase 2 |